AdAlta Ltd. (AU:1AD) has released an update.
Melbourne-based AdAlta Limited has announced the unanimous approval of all resolutions during its Extraordinary General Meeting, signaling strong shareholder support for its future share issuance plans related to investment facilities and corporate activities. The company, known for its proprietary i-body technology, is progressing with its lead candidate AD-214 for treating fibrotic diseases and expanding into advanced cellular immunotherapies for cancer through strategic collaborations and partnerships.
For further insights into AU:1AD stock, check out TipRanks’ Stock Analysis page.
